Browse by Audience
: The neuropeptide calcitonin gene-related peptide (CGRP) is recognized as a critical player in migraine pathophysiology. Excitement has grown regarding CGRP because of the development and clinical testing of drugs targeting CGRP or its receptor. While these drugs alleviate migraine symptoms in half of patients, the remaining unresponsive half of this population creates an impetus to address unanswered questions that exist in this field.: We describe the role of CGRP in migraine pathophysiology and CGRP-targeted therapeutics currently under development and in use. We also discuss how a second CGRP receptor may provide a new therapeutic target.: CGRP targeting drugs have shown a remarkable safety profile. We speculate that this may reflect the redundancy of peptides within the CGRP family and a second CGRP receptor that may compensate for reduced CGRP activity. Furthermore, we propose that an inherent safety feature of peptide-blocking antibodies is attributed to the fundamental nature of peptide release, which occurs as a large bolus in short bursts of volume transmission. These facts support the development of more refined CGRP therapeutic drugs, as well as drugs that target other neuropeptides. We believe that the future of migraine research is bright with exciting advances on the horizon.
Learn More >There is a major unmet need to develop new therapies for migraine. We have previously demonstrated the therapeutic potential of the acid sensing ion channel (ASIC) blockade in migraine, via an ASIC1 mechanism. ASIC3 is expressed in the trigeminal ganglion and its response is potentiated by nitric oxide that can trigger migraine attacks in patients, and thus we sought to explore the potential therapeutic effect of ASIC3 blockade in migraine.
Learn More >This article reviews current headache disability measures and clinical need, as well as presenting the rationale for a new measure addressing work-related disability in migraine patients and the steps devoted to this aim.
Learn More >This proposed systematic review will identify the existing evidence on medication-overuse headache in children and adolescents.
Learn More >In countries like India, many migraine patients presenting to primary care clinics fail to fulfill standard (ICHD 3) migraine diagnostic criteria. Since they do not present with typical ICHD 3 migraine diagnostic symptoms, it is necessary to define the criteria for atypical migraine. This would ensure that the patients receive the right treatment approach, both non-pharmacological and pharmacological. Looking for triggers, family history, activity affected and absolute normality in between attacks, past episodes of episodic syndromes, prodromal and oculonasal autonomic symptoms will help in identifying the migraine origin of these headaches.
Learn More >To determine the relationship between hormonal contraceptive (HC) use and painful symptoms, particularly those associated with headache and painful temporomandibular disorders (TMD).
Learn More >Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment.
Learn More >We aimed to evaluate associations of human leukocyte antigen variants with migraine or headache in hospital and population-based settings.
Learn More >